IMMUNOTECH BIOPHARM LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.43 HKD | +0.88% |
|
+9.24% | -31.40% |
| 03-29 | Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 | MT |
| 03-28 | Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Capitalization 1 | 4,833 | 7,061 | 2,104 |
| Enterprise Value (EV) 1 | 4,039 | 6,819 | 2,175 |
| P/E ratio | -9.49 x | -19.9 x | -6.6 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -12.1 x | -21 x | -9.41 x |
| EV / FCF | -41,571,620 x | -33,848,331 x | -14,859,534 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 4.29 x | 8.59 x | 4.14 x |
| Nbr of stocks (in thousands) | 514,584 | 514,584 | 514,584 |
| Reference price 2 | 9.393 | 13.72 | 4.089 |
| Announcement Date | 20/04/21 | 25/04/23 | 25/04/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net sales | - | - | - | - | - |
| EBITDA 1 | -42.32 | -92.1 | -334 | -324.3 | -231.1 |
| EBIT 1 | -44.3 | -97.73 | -347.7 | -345.2 | -274.2 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -34.89 | -109.1 | -439.1 | -354.6 | -321.1 |
| Net income 1 | -34.77 | -108.8 | -439 | -354.2 | -318.1 |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.1061 | -0.2900 | -0.9900 | -0.6900 | -0.6200 |
| Free Cash Flow | - | -65.45 | -97.16 | -201.4 | -146.3 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 29/06/20 | 29/06/20 | 20/04/21 | 25/04/23 | 25/04/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 70.3 |
| Net Cash position 1 | 140 | 243 | 794 | 242 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.3044 x |
| Free Cash Flow | - | -65.5 | -97.2 | -201 | -146 |
| ROE (net income / shareholders' equity) | - | -39% | -59.7% | -36.3% | -48.3% |
| ROA (Net income/ Total Assets) | - | -17.5% | -26.7% | -18.7% | -17.3% |
| Assets 1 | - | 620 | 1,644 | 1,895 | 1,835 |
| Book Value Per Share 2 | 0.6600 | 0.4400 | 2.190 | 1.600 | 0.9900 |
| Cash Flow per Share 2 | 0.3900 | 0.7400 | 1.640 | 0.6900 | 0.1100 |
| Capex 1 | 35.1 | 13.8 | 25 | 146 | 68.2 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 29/06/20 | 29/06/20 | 20/04/21 | 25/04/23 | 25/04/23 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.40% | 224M | |
| -1.65% | 103B | |
| +6.75% | 101B | |
| +7.02% | 23.07B | |
| -12.60% | 22.23B | |
| -5.10% | 18.05B | |
| -39.98% | 17.18B | |
| -10.17% | 16.94B | |
| +6.12% | 14.07B | |
| +35.47% | 12.35B |
- Stock Market
- Equities
- 6978 Stock
- Financials Immunotech Biopharm Ltd
